Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk addresses Mixtard 30 concerns

Novo Nordisk has responded to a claim that the company is planning to remove insulin, Mixtard 30, from the UK market

Novo Nordisk has responded to an exclusive story published in the Herald Scotland on June 9, which claimed the company is planning to remove insulin, Mixtard 30, from the UK market. 

According to the newspaper, the removal of Mixtard 30 would result in thousands of diabetic patients facing a change of medication and would place undue burden on the NHS.

Head of policy at Diabetes UK, Bridget Turner, commented that the removal of any insulin from the market goes against patient choice and will cause anxiety for people with diabetes.

"If there are any changes to the types of insulin available in the UK, pharmaceutical companies have a duty of care to provide time for those affected to liaise with their healthcare teams to discuss alternative treatments," Turner said.

Responding to a request for clarity regarding the article, the Danish drug maker stated that it had not made any announcements regarding Mixtard 30. "Novo Nordisk continually reviews its insulin portfolio as newer more innovative insulins are introduced. This has resulted in a gradual discontinuation of older animal and human insulins as modern insulins have become established in the UK," it said.

Novo Nordisk also said that any insulin portfolio changes would be communicated in "a timely and professional manner".

"We believe it is imperative that any communication is done in a way that minimises patient concern and ensures that healthcare professionals have the appropriate information to discuss the impact of any change with their individual patients and provide support and reassurance as needed," the spokesperson added.

11th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics